N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide hydrochloride | 588703-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-isopropyl-1-benzofuran-5-carboxamide hydrochloride
• 英文别名: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-3-propan-2-yl-1-benzofuran-5-carboxamide;hydrochloride
• CAS: 588703-24-6
• 化学式: C₁₉H₂₄N₂O₂*ClH
• 分子量: 348.873
• InChiKey: GKHGXWVDSJXDOI-LMOVPXPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  45.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Azabicyclic compounds for the treatment of disease
  申请人：——

  公开号：US20030232853A1

  公开（公告）日：2003-12-18

  The invention provides compounds of Formula I: 1 wherein Azabicyclo is 2 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中Azabicyclo是 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对已知涉及α7的药物具有用处。
• Compounds having both alpha7 nicotinic agonist activity and 5HT3 antagonist activity for the treatment of CNS diseases
  申请人：——

  公开号：US20040147522A1

  公开（公告）日：2004-07-29

  The invention discloses compounds that are selective &agr;7 nAChR agonists and 5-HT 3 antagonists. The compounds are useful for treating many CNS diseases.

  本发明揭示了一种选择性&agr;7 nAChR 激动剂和5-HT3拮抗剂的化合物。这些化合物可用于治疗许多中枢神经系统疾病。
• AZABICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1476448A2

  公开（公告）日：2004-11-17
• COMPOUNDS HAVING BOTH ALPHA7 NACHR AGONIST AND 5HT ANTAGONIST ACTIVITY FOR TREATMENT OF CNS DISEASES
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1562959A2

  公开（公告）日：2005-08-17
• Medical device lubricant comprising radiation curable silicon material
  申请人：Steube Alan Gregory

  公开号：US20050203201A1

  公开（公告）日：2005-09-15

  The invention relates to a lubricant for medical devices. The inventive lubricant uses silicone epoxy and vinyl ether that both rapidly cure when exposed to ultraviolet light or an intense electron beam. The lubricants formulated with these components in combination with a secondary silicone component and a photoinitator offer improved performance when compared to lubricants formulated from the prior art method of using a RTV+silicone fluid materials. The speed of the UV/EB cure of the new components makes lubricants formed from them more compatible with high speed manufacturing processes by eliminating the delay of prior art lengthy cure steps.